BioCentury | Mar 12, 2015
Company News

Management tracks

...from head of research and preclinical development. Croughs, who succeeds Pierre Vandepapeliere, was CMO at Cytheris S.A....
BioCentury | Nov 11, 2013
Company News

TxCell management update

...TxCell S.A. , Valbonne, France Business: Autoimmune Hired: Damian Marron as CEO, formerly CEO of Cytheris S.A....
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Autoimmune disease

...and using soluble IL-7R to enhance the antiviral effect of IL-7 in models for infection. Cytheris S.A.'s...
BioCentury | Oct 29, 2012
Clinical News

Recombinant IL-7 regulatory update

...in post-transplant patients with T cell depleted bone marrow or peripheral blood stem cell transplants. Cytheris S.A....
BioCentury | Jul 16, 2012
Clinical News

Recombinant IL-7 regulatory update

...The European Commission granted Orphan Drug designation for Cytheris' CYT107 to treat progressive multifocal leukoencephalopathy (PML...
...in post-transplant patients with T cell depleted bone marrow or peripheral blood stem cell transplants. Cytheris S.A....
BioCentury | Jun 18, 2012
Company News

Cytheris management update

Cytheris S.A. , Issy-les-Moulineaux, France Business: Infectious, Cancer Hired: Damian Marron as CEO, formerly CEO at Trophos S.A. WIR Staff cancer Infectious...
BioCentury | Jun 18, 2012
Company News

Trophos management update

...Transitioned: Christine Placet to CEO from CFO; she succeeds Damian Marron who becomes CEO of Cytheris S.A. WIR...
BioCentury | Mar 19, 2012
Clinical News

Recombinant IL-7: Additional Phase IIa data

...Cytheris previously reported data from 12 patients in the trial (see BioCentury, March 7, 2011). Cytheris S.A....
BioCentury | Nov 14, 2011
Clinical News

Recombinant IL-7: Interim Phase I/IIa data

...in San Francisco. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon alfa-2a and Copegus ribavirin. Cytheris S.A....
BioCentury | May 23, 2011
Clinical News

IL-7: Phase IIa started

...the first 14 days of a 21-day cycle. The center is sponsoring the trial, while Cytheris...
...T cell receptor of cells reconstituted by CYT107. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Cytheris S.A....
Items per page:
1 - 10 of 49
BioCentury | Mar 12, 2015
Company News

Management tracks

...from head of research and preclinical development. Croughs, who succeeds Pierre Vandepapeliere, was CMO at Cytheris S.A....
BioCentury | Nov 11, 2013
Company News

TxCell management update

...TxCell S.A. , Valbonne, France Business: Autoimmune Hired: Damian Marron as CEO, formerly CEO of Cytheris S.A....
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Autoimmune disease

...and using soluble IL-7R to enhance the antiviral effect of IL-7 in models for infection. Cytheris S.A.'s...
BioCentury | Oct 29, 2012
Clinical News

Recombinant IL-7 regulatory update

...in post-transplant patients with T cell depleted bone marrow or peripheral blood stem cell transplants. Cytheris S.A....
BioCentury | Jul 16, 2012
Clinical News

Recombinant IL-7 regulatory update

...The European Commission granted Orphan Drug designation for Cytheris' CYT107 to treat progressive multifocal leukoencephalopathy (PML...
...in post-transplant patients with T cell depleted bone marrow or peripheral blood stem cell transplants. Cytheris S.A....
BioCentury | Jun 18, 2012
Company News

Cytheris management update

Cytheris S.A. , Issy-les-Moulineaux, France Business: Infectious, Cancer Hired: Damian Marron as CEO, formerly CEO at Trophos S.A. WIR Staff cancer Infectious...
BioCentury | Jun 18, 2012
Company News

Trophos management update

...Transitioned: Christine Placet to CEO from CFO; she succeeds Damian Marron who becomes CEO of Cytheris S.A. WIR...
BioCentury | Mar 19, 2012
Clinical News

Recombinant IL-7: Additional Phase IIa data

...Cytheris previously reported data from 12 patients in the trial (see BioCentury, March 7, 2011). Cytheris S.A....
BioCentury | Nov 14, 2011
Clinical News

Recombinant IL-7: Interim Phase I/IIa data

...in San Francisco. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon alfa-2a and Copegus ribavirin. Cytheris S.A....
BioCentury | May 23, 2011
Clinical News

IL-7: Phase IIa started

...the first 14 days of a 21-day cycle. The center is sponsoring the trial, while Cytheris...
...T cell receptor of cells reconstituted by CYT107. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Xeloda. Cytheris S.A....
Items per page:
1 - 10 of 49